Skip to content

Improving Health Outcomes in HIV Immunologic Non-Responders

  • Dorrit Walsh
A conference call meeting initiated by HIV community advocates was held with FDA members on June 10, 2016 to discuss ways to advance the evaluation and development of products (drugs or biologics) that demonstrate promise in improving health outcomes in HIV-positive patients with inadequate immune response after long term successful HIV treatment.
Read more

An Open Letter to Senator Sanders Challenging the Characterization of Meeting with HIV/AIDS Activists

  • Chad Cipiti
Dear Senator Sanders: We are grateful that you took time to sit with us this week to discuss a broad range of issues related to the fight against HIV/AIDS. Our group represents a larger coalition of over 70 organizations and advocates from across the country who hope to use this opportunity to push forward the national conversation, which is sorely missing, about HIV/AIDS. While we were optimistic following what we felt was a productive meeting, our optimism quickly turned to disappointment when your campaign issued a news release misrepresenting the meeting with HIV/AIDS leadership entitled “Sanders Backs California Ballot Initiative to Rein in Drug Prices at Meeting with HIV/AIDS Advocates.”
Read more

Story: Cure for HIV Possible “Within Three Years”

  • Dorrit Walsh

April 2016 The Daily Telegraph article and examples of the media coverage that followed it: Cure for HIV possible within three years as scientists snip virus from cells– The Daily Telegraph, April 1, 2016. Update April 6, 2016: After receiving complaints, The Daily…

Read more

The Low Cost of Universal Access

  • Chad Cipiti

Generic treatments for HIV, viral hepatitis, and cancer can be affordably—and profitably—mass-produced for broad, unobstructed availability By Tracy Swan TAG talks with Andrew Hill, senior visiting research fellow in the University of Liverpool’s Department of Pharmacology, about his group’s work…

Read more

PrEP Pricing Problems

  • Chad Cipiti

A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified—cost shouldn’t be one of them By James Krellenstein and Jeremiah Johnson On July 16, 2012, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences’…

Read more

HIV Community Letter to Hillary for America

  • Chad Cipiti
Dear Secretary Clinton: We write to you in the sincere hope that we can work together to transform the pain caused by your March 11th mischaracterization of the Reagans’ role in the AIDS crisis into an urgently needed public discussion of a plan to end the United States HIV epidemic by the year 2025.
Read more

Pre-CROI Community HIV Cure Research Workshop 2016

  • Chad Cipiti

On Sunday February 21, 2016 in Boston, the AIDS Treatment Activists Coalition, AVAC, European AIDS Treatment Group, Project Inform and TAG co-sponsored a community workshop on HIV cure research. The workshop has become an annual event that takes place immediately…

Read more
Back To Top